Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that results in joint destruction and disability.[@R1] Levels of tumour necrosis factor alpha (TNF), an inflammatory cytokine, are elevated in the blood and synovial fluid of patients with RA, and may play a central role in its pathogenesis.[@R2]--[@R7]

Although infliximab, an anti-TNF antibody, exhibits excellent effectiveness in RA,[@R8]--[@R11] insufficient response to the standard treatment of infliximab (3 mg/kg per 8 weeks) has also been observed in some cases in clinical practice. Such patients are usually treated by dose escalation or by shortening the dose interval of the infliximab therapy.[@R12]--[@R15]

The RISING study (NCT00691028) is a randomised, double-blind clinical trial, which has shown that the clinical response to infliximab at a dose of 10 mg/kg is significantly higher than the response to 3 mg/kg infliximab, and that a trough serum level of 1 μg/ml is the threshold for clinical response.[@R16] However, clinical response to different dose levels of infliximab was significant only for American College of Rheumatology (ACR) improvement criteria and the European League Against Rheumatism (EULAR) responses, and the measurable difference was small.

Several clinical studies have attempted to address whether a higher dose of infliximab provides a better clinical response than standard doses in patients with RA.[@R8]--[@R11] [@R17] However, the results were not consistent among those studies. In addition, a randomised, double-blind study comparing dose escalation and continuation of the standard dose in patients with RA who had an insufficient response to 3 mg/kg of infliximab clearly demonstrated no beneficial response by dose escalation,[@R18] contrary to our results.

Although the standard dose of infliximab can be efficacious in a large proportion of patients with RA, some patients may require a higher dose of infliximab to achieve clinical response.[@R19] [@R20] The inconsistent results mentioned above might be explained by the different proportion of patients who might benefit from infliximab dose escalation in each study. Thus the clinical and immunological features of these patients who require higher dose of infliximab are not fully understood.

It is tempting to speculate that the production and resultant plasma levels of TNF, the target molecule of infliximab, exceeds the neutralising capacity of infliximab in insufficient responders who are unable to maintain the threshold serum level of infliximab. Considering that hypothesis, we analysed the RISING study data based on plasma TNF levels. We found that the clinical response of patients with high baseline levels of TNF (baseline-TNF) showed a significant improvement with higher doses of infliximab, whereas patients with low baseline-TNF did not have a better response even with higher doses of infliximab.

Methods {#s1}
=======

Patients and study protocol {#s2}
---------------------------

The study protocol was approved by the local institutional review board and was carried out in accordance with the Helsinki Declaration and good clinical practice. Patient enrollment criteria and study design have previously been described in detail.[@R16] In the RISING study, 327 patients with active RA, despite receiving previous treatment with methotrexate, were administered 3 mg/kg infliximab at weeks 0, 2 and 6 with methotrexate (open-label period weeks 0--14). Patients were randomly assigned into three groups using a dynamic allocation procedure based on the clinical response at week 10 and were treated with 3 (n=99), 6 (n=104), or 10 (n=104) mg/kg infliximab, every 8 weeks from weeks 14 to 46, with methotrexate (blinded period weeks 14--54).

Laboratory test values and serum infliximab measurement {#s3}
-------------------------------------------------------

Plasma samples for the evaluation of baseline-TNF were collected just before the first infusion of infliximab (week 0). The plasma was separated from EDTA-supplemented blood and was stored at −20 to −80°C. Baseline-TNF levels were measured by ELISA using the QantiGlo ELISA Kit (QTA00B; R&D Systems Inc, Minneapolis, Minnesota, USA) in Mitsubishi Chemical Medience Corporation (Tokyo, Japan). Recombinant human TNF included in the kit was used as reference. Mitsubishi Chemical Medience Corporation has made minor modifications on the assay procedure of the ELISA kit (<http://www.rndsystems.com/pdf/qta00b.pdf>) and has validated their detection limit. Since the mean relative light units (2 SD) at blank and 0.55 pg/ml were 15.2 (3.4) and 25.2 (5.0) by their modified procedure, respectively, the detection limit was determined as 0.55 pg/ml by adding 2 SD to the relative light units. The coefficient of variation or relative error values of intra-assay or inter-assay TNF were within 3.6% or 6.2%, respectively. They confirmed that freezing and thawing the plasma sample 10 times and storing at −20°C for 22 weeks did not affect the stability of TNF in the plasma.

Sera were collected at weeks 0 and 2 and every 4 weeks thereafter. The serum infliximab level was measured by ELISA using the anti-infliximab monoclonal antibody obtained from Centocor Ortho Biotech Inc. (Horsham, Pennsylvania, USA).[@R8] Serum infliximab levels below 0.1 µg/ml were undetectable.

Baseline rheumatoid factor (RF) was measured by the latex agglutination test. Antibodies against cyclic citrullinated peptides (CCP) and matrix metalloproteinase-3 (MMP-3) levels were measured by ELISA. The detectable ranges were as follows: RF, 3 IU/ml or greater; anti-CCP antibodies, 0.6 IU/ml or greater to 100 IU/ml or less; and MMP-3, 12.5 ng/ml or greater.

Evaluation of efficacy {#s4}
----------------------

The clinical response to infliximab was evaluated using EULAR criteria, and disease activity was assessed using the disease activity score in 28 joints (DAS28) based on C-reactive protein (CRP) and the ACR core set[@R21] at week 54. The EULAR response was evaluated using the DAS28 based on the erythrocyte sedimentation rate (ESR) assessment method (<http://www.reuma-nijmegen.nl/www.das-score.nl/index.html>). The cut-off values for DAS28--CRP were as follows, based on a report from Inoue *et al*.[@R22]: DAS28--CRP remission, less than 2.3; low disease activity (LDA), 2.3 or greater to less than 2.7; moderate disease activity (MDA), 2.7 or greater to 4.1 or less; high disease activity (HDA), greater than 4.1. Joint damage was assessed by the total modified Sharp score (0--390 points).[@R23]

Analytical method {#s5}
-----------------

The clinical responses to infliximab at week 54 were analysed for the full analysis set using the last observation carried forward approach. For the comparison of clinical response among dose groups (3, 6 and 10 mg/kg), logistic regression analysis was performed using the clinical responses at the time of randomisation (week 10) as a covariate.

Because there is no well-established threshold value for an abnormal TNF level in the ELISA kit used, the detection limit, less than 0.55 pg/ml, and a threefold higher level, 1.65 pg/ml, were adopted as cut-off values, and the patients were stratified into the following three patient groups for analysis: low, less than 0.55 pg/ml (TNF-low); intermediate, 0.55 pg/ml or greater to less than 1.65 pg/ml (TNF-int); and high, 1.65 pg/ml or greater (TNF-high).

The association of baseline-TNF with baseline disease activity and the efficacy of infliximab therapy was analysed for the three groups described above (TNF-low, TNF-int and TNF-high patients) employing the Kendall rank correlation coefficient. Baseline disease activity was analysed for the enrolled patients (n=327). Clinical responses (DAS28--CRP or ACR core set) and efficacy on physical function (improved health assessment questionnaire (HAQ) score) at week 54 were analysed using the last observation carried forward approach (n=307). Radiographic progression was analysed in the patients whose radiographic data were obtained at week 54 (n=273). The association between the serum infliximab level and clinical response or disease activity at week 54 was analysed in the patients for whom both serum levels and DAS28--CRP values were obtained at week 54 (n=271).

Primary non-responders were defined as patients who had not achieved LDA throughout the study period (at weeks 2--54), and secondary non-responders as those who had not achieved LDA at week 54 but had achieved it at least once between weeks 2 and 50. Kruskal--Wallis test analysis was performed to compare the rates of TNF-low, TNF-int and TNF-high patients in primary and secondary non-responders versus responders (those who had achieved LDA at week 54).

Results {#s6}
=======

Patients\' background and association between baseline-TNF and parameters of disease activity at baseline {#s7}
---------------------------------------------------------------------------------------------------------

[Table 1](#T1){ref-type="table"} shows the baseline demographics and clinical characteristics of the enrolled patients (n=327). The median (IQR), minimum and maximum baseline-TNF values were 0.92 pg/ml (\<0.55--1.29 pg/ml), less than 0.55 pg/ml and 9.68 pg/ml, respectively. The proportion of patients with baseline-TNF values less than 0.55 pg/ml (undetectable), 0.55 pg/ml or greater to less than 1.65 pg/ml, and 1.65 pg/ml or greater (TNF-low, TNF-int and TNF-high patients) was 28.7%, 58.4% and 12.8%, respectively. Details on the distribution of baseline-TNF can be found in supplementary [figure 1](#F1){ref-type="fig"} (available online only). Baseline-TNF was significantly, but slightly, correlated with most parameters of disease activity and HAQ score, but not with radiographic progression ([table 2](#T2){ref-type="table"}). The significant correlations of baseline-TNF with RF and anti-CCP antibodies were also observed.

![Clinical responses to infliximab therapy in patients with rheumatoid arthritis at week 54. The European League Against Rheumatism response criteria and disease activity were measured by the disease activity score in 28 joints (DAS28)--C-reactive protein (CRP) using the last observation carried forward method. Disease activity was defined as high disease activity, DAS28--CRP greater than 4.1; moderate disease activity, 2.7 or greater to 4.1 or less; low disease activity, 2.3 or greater to less than 2.7; and DAS28--CRP remission, less than 2.3. \*p\<0.05 versus the 3 mg/kg groups.](ard-70-6-1208-fig1){#F1}

###### 

Baseline demographics and clinical characteristics of patients enrolled in the RISING study (n=327)

                                                                                    Baseline value
  --------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------
  Age, year                                                                         49.9 (12.0)
  Gender, female                                                                    267 (81.7)[\*](#T1FN1){ref-type="table-fn"}
  Disease duration, years                                                           8.2 (8.0)
  Steinbrocker stage                                                                
   I                                                                                32 (9.8)[\*](#T1FN1){ref-type="table-fn"}
   II                                                                               114 (34.9)[\*](#T1FN1){ref-type="table-fn"}
   III                                                                              105 (32.1)[\*](#T1FN1){ref-type="table-fn"}
   IV                                                                               76 (23.2)[\*](#T1FN1){ref-type="table-fn"}
  Steinbrocker functional class                                                     
   1                                                                                58 (17.7)[\*](#T1FN1){ref-type="table-fn"}
   2                                                                                239 (73.1)[\*](#T1FN1){ref-type="table-fn"}
   3                                                                                30 (9.2)[\*](#T1FN1){ref-type="table-fn"}
   4                                                                                0 (0.0)[\*](#T1FN1){ref-type="table-fn"}
  Duration of methotrexate use, years                                               2.7 (2.8)
  Methotrexate dose, mg/week                                                        7.8 (1.7)
  Glucocorticoid use                                                                223 (68.2)[\*](#T1FN1){ref-type="table-fn"}
  DAS28--CRP                                                                        5.5 (4.9, 6.2)[†](#T1FN2){ref-type="table-fn"}
  DAS28--ESRTJC, 68 joints                                                          6.2 (5.6, 6.8)[†](#T1FN2){ref-type="table-fn"}15.0 (10.0, 23.0)[†](#T1FN2){ref-type="table-fn"}
  SJC, 66 joints                                                                    12.0 (9.0, 17.0)[†](#T1FN2){ref-type="table-fn"}
  CRP, mg/dl                                                                        2.4 (1.2, 4.1)[†](#T1FN2){ref-type="table-fn"}
  ESR, mm/h                                                                         52 (35, 72)[†](#T1FN2){ref-type="table-fn"}
  Patient pain VAS, mm                                                              54 (39, 72)[†](#T1FN2){ref-type="table-fn"}
  Patient global VAS, mm                                                            54 (36, 72)[†](#T1FN2){ref-type="table-fn"}
  Physician global VAS, mm                                                          64 (50, 78)[†](#T1FN2){ref-type="table-fn"}
  TSS[‡](#T1FN3){ref-type="table-fn"}                                               35.5 (11.5, 73.4)[†](#T1FN2){ref-type="table-fn"}
  Estimated yearly progression of TSS, point/year[‡](#T1FN3){ref-type="table-fn"}   6.1 (3.1, 11.4)[†](#T1FN2){ref-type="table-fn"}
  HAQ                                                                               1.1 (0.8, 1.6)[†](#T1FN2){ref-type="table-fn"}
  RF value, IU/ml                                                                   90 (36, 223)[†](#T1FN2){ref-type="table-fn"}
  Anti-CCP antibodies value, IU/ml                                                  ≥100 (28, ≥100)[†](#T1FN2){ref-type="table-fn"}
  MMP-3 value, ng/ml                                                                219 (105, 419)[†](#T1FN2){ref-type="table-fn"}

Data in baseline values are mean (SD),

number of patients (%), or

median (IQR).

Health assessment questionnaire (HAQ) score: scores can range from 0 (no difficulty) to 3 (unable to perform this activity).

Total modified Sharp score (TSS): scores can range from 0 to 390 (erosion score 0--230, joint space narrowing score 0--160), with high scores indicating more joint damage. Estimated yearly rate of progression of the TSS was based on the duration of disease and baseline TSS for every patient.

n=325.

CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS 28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; MMP-3, matrix metalloproteinase 3; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.

###### 

Baseline disease activities in TNF-low, TNF-int and TNF-high patients

                                                    Baseline-TNF                                                                                                                 
  ------------------------------------------------- ---------------------------------------------------- --------------------------------------------------- ------------------- ---------
  DAS28-CRP                                         5.3 (4.9, 5.9)                                       5.5 (5.0, 6.2)                                      5.9 (5.2, 6.7)      0.002
  DAS28-ESR                                         5.9 (5.5, 6.4)                                       6.2 (5.7, 6.8)                                      6.8 (6.2, 7.3)      \<0.001
  TJC, 68 joints                                    14.0 (10.0, 21.0)                                    15.0 (11.0, 23.0)                                   16.5 (12.0, 23.0)   0.153
  SJC, 66 joints                                    11.0 (8.0, 16.0)                                     13.0 (9.0, 17.0)                                    12.5 (10.0, 18.0)   0.041
  Patient pain VAS, mm                              49.0 (37.0, 65.0)                                    58.0 (40.0, 72.0)                                   68.5 (46.0, 88.0)   \<0.001
  Patient global VAS, mm                            51.0 (36.0, 64.0)                                    56.0 (36.0, 72.0)                                   65.0 (43.0, 86.0)   0.016
  Physician global VAS, mm                          62.0 (50.0, 75.0)                                    65.0 (49.0, 77.0)                                   72.0 (51.0, 82.0)   0.081
  CRP (mg/dl)                                       2.0 (1.0, 3.9)                                       2.4 (1.2, 3.9)                                      2.8 (1.4, 5.8)      0.028
  ESR (mm/h)                                        46.0 (33.0, 65.0)                                    53.0 (35.0, 72.0)                                   67.5 (40.0, 89.0)   0.001
  HAQ                                               1.0 (0.5, 1.4)                                       1.1 (0.9, 1.6)                                      1.4 (1.0, 2.1)      0.002
  TSS                                               37.0 (10.5, 76.0)[\*](#T2FN1){ref-type="table-fn"}   36.0 (12.5, 72.3)[†](#T2FN2){ref-type="table-fn"}   22.5 (13.0, 56.0)   0.960
  Estimated yearly progression of TSS, point/year   5.8 (2.8, 12.0)[\*](#T2FN1){ref-type="table-fn"}     6.3 (3.4, 11.3)[†](#T2FN2){ref-type="table-fn"}     5.5 (2.5, 10.0)     0.833
  RF value, IU/ml                                   85 (27, 215)                                         81 (37, 167)                                        238 (126, 554)      0.007
  Anti-CCP antibodies value, IU/ml                  91 (17, ≥100)                                        ≥100 (30, ≥100)                                     ≥100 (≥100, ≥100)   0.012
  MMP-3 value, ng/ml                                205 (105, 377)                                       216 (102, 391)                                      268 (114, 640)      0.214

Data in baseline value are median (IQR).

Baseline disease activities were evaluated in the patients enrolled in the RISING study (n=327). The associations of baseline-tumour necrosis factor alpha (TNF) with baseline disease activities were analysed in the three groups (TNF-low, TNF-int and TNF-high patients) employing the Kendall rank correlation coefficient.

n=93.

n=190.

CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MMP-3, matrix metalloproteinase 3; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TSS, total modified Sharp score; VAS, visual analogue scale.

Clinical response to infliximab at week 54 {#s8}
------------------------------------------

Of the enrolled patients, 307 were treated with 3, 6 or 10 mg/kg infliximab during the blinded period, and clinical response was evaluated at week 54 using DAS28--CRP ([figure 1](#F1){ref-type="fig"}). The clinical responses at week 54 were significantly higher in the 10 mg/kg group than in the 3 mg/kg group, and 45.2% of the patients in the 10 mg/kg group achieved DAS28--CRP remission.

Association between baseline-TNF and the efficacy of infliximab therapy at week 54 {#s9}
----------------------------------------------------------------------------------

The EULAR responses and disease activities at week 54 in TNF-low (n=87), TNF-int (n=180), and TNF-high (n=40) patients are shown in [figure 2A,B](#F2){ref-type="fig"}. In TNF-low patients, the clinical response was similar among the 3, 6 and 10 mg/kg groups, showing no dose dependency. In TNF-int patients, the EULAR response rate increased and disease activity decreased as the dose increased, but without significant difference. For TNF-high patients, the clinical response and disease activity were significantly better at 10 mg/kg than at 3 mg/kg and 6 mg/kg. The good response rates were 14%, 31% and 60% in the 3, 6 and 10 mg/kg groups, respectively, and the DAS28--CRP remission rates were 7%, 31% and 50%, respectively. A similar influence by baseline-TNF was also noted on the ACR core set ([figure 2C](#F2){ref-type="fig"}). Significant dose dependency was observed only in TNF-high patients.

![Correlation of plasma tumour necrosis factor alpha (TNF) levels before infliximab therapy (baseline-TNF) with (A) the European League Against Rheumatism (EULAR) response, (B) the disease activity score in 28 joints (DAS28) and (C) American College of Rheumatology (ACR) core set at week 54. Patients were divided into three patients groups by the baseline-TNF level as follows: TNF-low patients, less than 0.55 pg/ml; TNF-int patients, 0.55 pg/ml or greater to less than 1.65 pg/ml; and TNF-high patients, 1.65 pg/ml or greater. EULAR response criteria for disease activity were measured by DAS28--C-reactive protein (CRP). Disease activity was defined as high disease activity (HDA), DAS28--CRP greater than 4.1; moderate disease activity (MDA), 2.7 or greater to 4.1 or less; low disease activity (LDA), 2.3 or greater to less than 2.7; and DAS28--CRP remission, less than 2.3. All clinical responses were evaluated by using the last observation carried forward method. \*Kendall rank correlation coefficient.](ard-70-6-1208-fig2){#F2}

Baseline-TNF at clinical response is shown in supplementary table 1 (available online only). Clinical response was significantly influenced by baseline-TNF in the 3 mg/kg group, but not in the 6 and 10 mg/kg groups. Baseline-TNF also influenced the improving physical function, in which the improvement in the HAQ score values and the rates of patients with meaningful improvement (\>0.22) in all dosage groups were significantly different in TNF-high patients (supplementary table 2, available online only). Meanwhile, none of the groups showed significant association with radiographic progression.

The proportions of TNF-low, TNF-int and TNF-high patients in responders (n=148) were 34.5%, 56.8% and 8.8%, respectively. On the other hand, those of primary non-responders (n=88) were 21.6%, 62.5% and 15.9%, and those of secondary non-responders (n=71) were 23.9%, 57.7% and 18.3%, respectively. Significant differences were observed between the responders and both of the non-responders (p=0.016 and p=0.032, respectively).

Association between baseline-TNF and serum infliximab level {#s10}
-----------------------------------------------------------

Clinical response to infliximab has been shown to be influenced by trough serum infliximab levels, and the threshold level for clinical response is approximately 1 μg/ml.[@R20] [@R24] In this study, the median (IQR) serum infliximab level at week 54 in patients with EULAR good response, moderate response and no response was 3.1 (1.2--7.1), 1.2 (\<0.1--3.6) and less than 0.1 (\<0.1--0.4) μg/ml. The median (IQR) level in patients in DAS28--CRP remission, with LDA, with MDA and with HDA at week 54 was 3.4 (1.5--7.5), 2.1 (0.4--4.7), 1.4 (\<0.1--4.0) and less than 0.1 (\<0.1--0.7) μg/ml, respectively. A significant association was observed between clinical response or disease activity and the serum infliximab level (both p\<0.001). In patients with high trough serum infliximab levels, better clinical responses were attained. Meanwhile, in patients with poor clinical response (EULAR no response, high disease activity), the median trough serum level was undetectable (\<0.1 μg/ml).

Baseline-TNF greatly affected the serum infliximab levels ([figure 3A--C](#F3){ref-type="fig"}). In TNF-low patients, the median trough serum infliximab levels were equivalent to or greater than the threshold level (1 μg/ml) in all groups (3, 6 and 10 mg/kg). For TNF-int patients, the 3 mg/kg dose did not achieve the threshold level of infliximab but did provide a detectable level (≥0.1 μg/ml). However, in TNF-high patients, the median trough serum infliximab levels were undetectable at both 3 and 6 mg/kg doses, in contrast to the 10 mg/kg dose, at which a high level (\>2 μg/ml) was maintained.

![Serum infliximab levels in (A) tumour necrosis factor alpha (TNF)-low, (B) TNF-int and (C) TNF-high patients. Patients were divided into three groups by the plasma TNF level before infliximab therapy (baseline-TNF) as follows: TNF-low patients, less than 0.55 pg/ml; TNF-int patients, 0.55 pg/ml or greater to less than 1.65 pg/ml; and TNF-high patients, 1.65 pg/ml or greater. Serum infliximab levels were measured by ELISA.](ard-70-6-1208-fig3){#F3}

The positive rates for anti-infliximab antibodies (human antichimeric antibodies; HACA), which is reported to influence the serum infliximab level[@R25] were 27.3%, 23.1% and 12.5% in the 3, 6 and 10 mg/kg dose levels, respectively. In patients who were negative for HACA, the serum infliximab level was also lower in TNF-high patients than in TNF-low patients, and the median serum infliximab levels at the 3 mg/kg dose at week 54 in TNF-low patients (n=23), TNF-int patients (n=37) and TNF-high patients (n=8) were 1.0, 0.6 and 0.2 µg/ml, respectively.

Association between safety and baseline-TNF or serum infliximab level {#s11}
---------------------------------------------------------------------

The incidences of adverse events (total, serious events, infection, serious infection, or infusion reaction) were almost comparable among patients receiving 3, 6 and 10 mg/kg doses in TNF-low, TNF-int and TNF-high patients. We could find no clear association between the incidence of adverse events and the trough serum level of infliximab either (supplementary table 3, available online only).

Discussion {#s12}
==========

Although dose escalation or shortening of the administration interval between administrations has been used for patients with RA who show an insufficient response to the standard dose of infliximab (3 mg/kg for 8 weeks after initial induction), the effectiveness of these countermeasures is still controversial.[@R18]--[@R20] [@R26]--[@R32] In this report, we hypothesised that the production and resultant plasma level of TNF exceeds the neutralising capacity of infliximab in insufficient responders; and that infliximab is consumed to neutralise the TNF, decreasing the serum infliximab level in those patients.

In our study, clinical responses at doses of 3, 6 and 10 mg/kg of infliximab were comparable in TNF-low patients, and the minimum serum infliximab level required for clinical response (approximately 1 μg/ml) was maintained, even in the 3 mg/kg group. Accordingly, the maximal clinical responses can be achieved even with 3 mg/kg therapy in TNF-low patients. In other words, dose escalation does not provide any benefit in this population. In contrast, in TNF-high patients, clinical responses at 3 and 6 mg/kg were significantly decreased in comparison with the response to a 10 mg/kg dose. The trough serum infliximab levels were 'undetectable' at 3 and 6 mg/kg but were greater than 2 μg/ml with a 10 mg/kg dose. As the association between baseline-TNF and the serum infliximab level was also observed in HACA-negative patients, this association was not reflected by the presence of HACA status.

It has been suggested that the threshold serum level for infliximab efficacy on radiographic progression might be lower than that for clinical response.[@R33] In this study, approximately 90% of the patients whose serum level could be maintained over the threshold for radiographic progression, including even TNF-high patients, showed no radiographic progression. It may explain why baseline-TNF status had no influence on radiographic progression as observed in this study.

The present report has demonstrated that higher doses of infliximab exhibited significantly better clinical and functional response in patients with high baseline-TNF, whereas clinical and functional response was comparable among patients administered 3, 6 and 10 mg/kg of infliximab with low baseline-TNF.

We had reported previously that there was no difference in the safety profile among groups receiving 3, 6 or 10 mg/kg.[@R16] The rates of adverse events were almost comparable among all dosage groups in TNF-low, TNF-int and TNF-high patients. However, it has been reported that high-dose infliximab therapy might increase the risk of adverse events.[@R11] [@R34] [@R35] So, the balance between risk and benefit should be considered at the time of infliximab dose escalation, even in TNF-high patients.

There have been several reports on the association between TNF level and the efficacy of infliximab.[@R36]--[@R39] Although the reason for the inconsistent results is unclear, the serum TNF level was measured by bioassay in the report by Marotte *et al*,[@R37] which is different from this study, in which ELISA was employed. In the studies by Wijbrandts *et al*,[@R38] clinical response was evaluated at week 16, 2 weeks after infliximab administration when a high serum infliximab level may have been maintained even in patients with a high baseline-TNF. These differences may have led to the different conclusions.

In the RISING study, baseline-TNF was measured in one institution (Mitsubishi Chemical Medience Corporation) concurrently, where minor modifications were made in the original assay procedure and validated for the commercial use of clinical samples.

It was reported that RF in the samples may cause false-positive results in immunoassays by cross-linking the capture and detection antibodies.[@R40] In our study, a significant correlation was observed between TNF and RF at baseline (τ value 0.129, p\<0.001). However, the maximum baseline RF level was 1560 IU/ml in patients with undetectable baseline-TNF (supplementary figure 2, available online only). Therefore, we considered that RF might interfere with the assay of TNF in patients with greater than 1560 IU/ml, but not in patients with less than 1560 IU/ml. Furthermore, we freshly collected the plasma samples from 39 patients with RA (in which backgrounds were shown in supplementary table 4, available online only), and carried out several tests to evaluate the effects of RF on the ELISA for TNF: 'RF-blocking test', using 40% mouse serum, 20% goat serum and 20% rabbit serum;[@R41] [@R42] 'IgM-RF adding test', using purified polyclonal IgM--RF (Interference Check RF Plus; Sysmex Corporation, Kobe, Japan); 'mismatch simplex sandwich test',[@R42] using anti-interleukin 6 antibodies conjugated to horseradish peroxidase from the QantiGlo ELISA Kit for interleukin 6 (Q6000B; R&D Systems Inc) as the detection antibodies. As we did not find a clear signal indicating that RF interacted with our ELISA for TNF, we considered that the TNF levels in our study were not influenced by RF (supplementary tables 5--7, available online only).

The circulating TNF level in patients with RA varied from several pg/ml to greater than 100 pg/ml in different reports.[@R43]--[@R46] Although the patient background should be considered in determining the cause of the variation, the measurement systems used for detecting circulating TNF levels in individual studies may largely account for the variation. In that regard, the cut-off values for baseline-TNF used in this report (0.55 and 1.65 pg/ml) were not absolute, and the titre should be standardised in the future.

So far, some of the patient backgrounds have been investigated for predictors of their clinical response to infliximab. Baseline CRP was reported to be associated with the serum infliximab level,[@R47] but no consensus has been obtained about the correlation between baseline CRP and clinical response.[@R36] [@R48] We investigated the influence of baseline CRP on the clinical response as an index of EULAR response as done by baseline-TNF. However, we could find no clear relationship between them (supplementary figure 3A,B, available online only). Given that TNF is one of the key cytokines that induce CRP in various inflammatory diseases such as RA, it is reasonable that baseline-TNF, rather than CRP, would be a good predictor of clinical response to the TNF inhibitor, infliximab.

Many contradictory reports have been published regarding the effectiveness of dose escalation with infliximab.[@R18]--[@R20] [@R26]--[@R32] The reason why no consensus has been reached is that dose escalation is significant only in TNF-high patients, so the results of reports have been influenced by the number of patients with high baseline-TNF included in those studies. In the RISING study, TNF-high patients accounted for approximately 13% of the total.

This study may provide insight into our understanding of the relationship between the concentration of circulating cytokines and the dose of antibodies against the cytokines in the treatment of RA. As mentioned by van Vollenhoven,[@R26] an attempt to apply results obtained under highly controlled circumstances at the group level to the unique individual is necessary. These results may be useful for establishing treatment strategies, such as the appropriate dose of infliximab in accordance with baseline-TNF in patients with RA, not only in daily clinical practice but also in relation to the economics of health care.
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